Purpose: We planned this prospective study to evaluate PSMA expression in recurrent high-grade gliomas (rHGG), including anaplastic astrocytoma and glioblastoma using Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68 (HBED-CC)]- (Ga-68 PSMA) positron emission tomography (PET), with its theranostic potential in mind.
Methods: This was a prospective study enrolling patients with clinical and MRI evidence of rHGG on follow-up. Three treated cases of HGG with RN on MRI were also included as negative controls. Abnormal tracer accumulation in the brain parenchyma, more than the contralateral hemisphere was interpreted as positive study. For semiquantitative analysis, a 3D spherical region of interest (ROI) was drawn around the site of the abnormal Ga-68 PSMA uptake, and the ratio of SUVmax of tumor (T) to SUVmax of the contralateral corresponding area (TBR) was calculated. Each patients' PSMA brain PET was fused to the corresponding MRI and reviewed for concordance.
Results: Thirty patients were included in the study, a total of 49 lesions were detected on MRI, and fused PET/MR images showed increased Ga-68 PSMA uptake in all these lesions. Multifocal lesions were better appreciated on fused PET-MR images, and concordance between MRI and PET was 100 % for patient and lesion-wise detection. Recurrent glioma lesions showed SUVmax and SUVmean values (median and IQR) 6.0 (4.4-8.2) and 3.3 (2.8-3.7), respectively. Lesions labeled as radiation necrosis on MRI did not show tracer accumulation.
Conclusion: Ga-68 PSMA has potential utility for evaluating recurrence in HGG and its potential for theranostics would encourage its use in the evaluation of these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00234-021-02828-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Baseline Ga-68 PSMA PET-Derived Primary Tumor Parameters in Patients with Prostate Cancer and Their Association with Clinical Risk Stratification and Clinicopathologic Features.
World J Nucl Med
December 2024
Department of Nuclear Medicine, Atatürk Training and Research Hospital, İzmir Kâtip Çelebi University, Izmir, Türkiye.
This article evaluates whether parameters derived from the gallium-68-labeled prostate-specific membrane antigen ( Ga-PSMA) positron emission tomography/computed tomography (PET/CT) imaging studies of primary prostate cancer (PCa) lesions were associated with Gleason score (GS), D'Amico risk class, Candiolo nomograms, and the metastatic status of the disease. We retrospectively evaluated newly diagnosed PCa patients who underwent Ga-PSMA PET/CT before therapy. Age, baseline serum prostate-specific antigen (PSA), and metastatic status were recorded.
View Article and Find Full Text PDFSynthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer Targeting Prostate Cancer.
ACS Med Chem Lett
November 2024
Radiochemical Studies Laboratory, INRASTES, N.C.S.R. "Demokritos", Agia Paraskevi Attikis, 15310 Athens, Greece.
Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) have been used for diagnostic molecular imaging/therapy of prostate cancer (PCa). To address tumor heterogeneity, we synthesized and evaluated a bispecific PSMA/GRPR ligand () combining PSMA-617 () and the GRPR antagonist RM2 () with the radiometal chelator DOTA. was radiolabeled with Ga ([Ga]Ga-) and Lu ([Lu]Lu-).
View Article and Find Full Text PDFClinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial.
Eur Urol Open Sci
December 2024
Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Article Synopsis
- The study investigates the feasibility and short-term outcomes of a new treatment for prostate cancer recurrence called PSMA radioguided salvage pelvic lymph node dissection (S-PLND), which helps detect and remove cancerous lymph nodes using advanced imaging techniques.
- In a group of 14 patients, results showed that the majority (93%) had successful detection and removal of cancerous targets, and there were no complications from the procedure, indicating its safety.
- Although some patients experienced a decline in prostate-specific antigen (PSA) levels after surgery, further research is needed to refine patient selection and understand the long-term clinical benefits of this treatment.
Rapid Concentration of Ga-68 and Proof-of-Concept Microscale Labeling of [Ga]Ga-PSMA-11 in a Droplet Reactor.
Molecules
September 2024
Crump Institute for Molecular Imaging, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.
The radiometal gallium-68 (Ga-68) has garnered significant interest due to its convenient production via compact and widely available generators and the high performance of Ga-labeled compounds for positron-emission tomography (PET) imaging for cancer diagnosis and management of patients undergoing targeted radionuclide therapy. Given the short half life of Ga-68 (68 min), microfluidic-based radiosynthesis is a promising avenue to establish very rapid, efficient, and routine radiolabeling with Ga-68; however, the typical elution volume of Ga-68 from a generator (4-10 mL) is incompatible with the microliter reaction volumes of microfluidic devices. To bridge this gap, we developed a microscale cartridge-based approach to concentrate Ga-68.
View Article and Find Full Text PDFBrain Metastatic Prostate Adenocarcinoma: Avoiding Mistaken Identities.
Cureus
September 2024
Radiation Medicine, University of Kentucky, Lexington, USA.
Article Synopsis
- Brain metastatic carcinoma from prostate cancer is uncommon, but identification through imaging like [Ga]PSMA PET/CT can be complicated by other brain tumors that also show uptake.
- A 70-year-old male with high-risk prostate cancer had a solitary brain lesion confirmed as metastatic adenocarcinoma after surgical resection, followed by targeted Gamma Knife radiosurgery and androgen deprivation therapy.
- The case highlights the importance of confirming the diagnosis histologically and shows that with appropriate treatment, significant control of the cancer can be achieved, even in rare brain metastases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!